-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-519260-41-00
6
2020-07-15
Hormonal contraception
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-513637-20-00
4
2017-03-24
Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-517817-34-00
9
2025-06-18
Gastric Cancer
-
2024-512504-19-00
1
2025-05-28
solid tumors
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-516814-39-00
5
2025-05-20
Chronic rhinosinusitis with nasal polyps
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-514594-21-00
5
2025-03-13
Heterozygous Familial Hypercholesterolemia
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-509069-19-00
4
2024-12-12
idiopathic pulmonary fibrosis